Maxime Verhoeven

230 Chapter 13 21. Smolen, J. S. & Aletaha, D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 63 , 43–52 (2011). 22. van Onna, M. et al. Assessment of disease activity in patients with rheumatoid arthritis using optical spectral transmission measurements, a non-invasive imaging technique. Ann. Rheum. Dis. 75 , 511–518 (2016). 23. Haavardsholm, E. A. et al. Monitoring anti-TNFα treatment in rheumatoid arthritis: Responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. Ann. Rheum. Dis. 68 , 1572–1579 (2009). 24. Xu, H., Zhang, Y., Zhang, H., Wang, C. & Mao, P. Comparison of the clinical effectiveness of US grading scoring system vs MRI in the diagnosis of early rheumatoid arthritis (RA). J. Orthop. Surg. Res. 12 , 152 (2017). 25. Hameed, B., Pilcher, J., Heron, C. & Kiely, P. D. W. The relation between composite ultrasound measures and the DAS28 score, its components and acute phase markers in adult RA. Rheumatology 47 , 476–480 (2008). 26. Haavardsholm, E. A. et al. Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ 354 , i4205 (2016). 27. Mandl, P. & Aletaha, D. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology 58 , 2091–2098 (2019). 28. Besselink, N. J. et al. Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis. Trials 20 , 226 (2019). 29. Aletaha, D. & Smolen, J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin. Exp. Rheumatol. 23 , s100–s108 (2005).